RTW Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-1,640,559
| Closed | -$314M | – | 70 |
|
|
2023
Q4 | $314M | Sell |
1,640,559
-42,803
| -3% | -$7.29M | 4.91% | 7 |
|
|
2023
Q3 | $298M | Hold |
1,683,362
| – | – | 6.29% | 4 |
|
|
2023
Q2 | $320M | Hold |
1,683,362
| – | – | 6.09% | 3 |
|
|
2023
Q1 | $337M | Hold |
1,683,362
| – | – | 7.02% | 3 |
|
|
2022
Q4 | $400M | Hold |
1,683,362
| – | – | 8.17% | 1 |
|
|
2022
Q3 | $337M | Hold |
1,683,362
| – | – | 7.77% | 1 |
|
|
2022
Q2 | $246M | Hold |
1,683,362
| – | – | 6.34% | 1 |
|
|
2022
Q1 | $275M | Sell |
1,683,362
-292,517
| -15% | -$44.6M | 5.69% | 1 |
|
|
2021
Q4 | $335M | Buy |
1,975,879
+292,517
| +17% | +$54.4M | 4.89% | 3 |
|
|
2021
Q3 | $318M | Hold |
1,683,362
| – | – | 4.79% | 3 |
|
|
2021
Q2 | $285M | Hold |
1,683,362
| – | – | 4.31% | 3 |
|
|
2021
Q1 | $238M | Buy |
1,683,362
+1,717
| +0.1% | +$258K | 3.71% | 5 |
|
|
2020
Q4 | $219M | Hold |
1,681,645
| – | – | 3.67% | 6 |
|
|
2020
Q3 | $245M | Hold |
1,681,645
| – | – | 5.9% | 3 |
|
|
2020
Q2 | $249M | Hold |
1,681,645
| – | – | 7.01% | 2 |
|
|
2020
Q1 | $183M | Buy |
1,681,645
+43,781
| +3% | +$5.05M | 7.88% | 2 |
|
|
2019
Q4 | $189M | Sell |
1,637,864
-129,764
| -7% | -$12.9M | 7.12% | 2 |
|
|
2019
Q3 | $142M | Sell |
1,767,628
-430,466
| -20% | -$34.1M | 8.45% | 2 |
|
|
2019
Q2 | $159M | Buy |
2,198,094
+1,362,221
| +163% | +$105M | 8.52% | 2 |
|
|
2019
Q1 | $78.1M | Buy |
835,873
+396,375
| +90% | +$33.2M | 5.33% | 4 |
|
|
2018
Q4 | $32M | Buy |
439,498
+50,426
| +13% | +$3.88M | 2.94% | 12 |
|
|
2018
Q3 | $34.1M | Buy |
389,072
+36,872
| +10% | +$3.71M | 2.04% | 14 |
|
|
2018
Q2 | $34.7M | Buy |
352,200
+105,971
| +43% | +$10.5M | 2.5% | 12 |
|
|
2018
Q1 | $29.3M | Sell |
246,229
-112,545
| -31% | -$14.5M | 2.79% | 10 |
|
|
2017
Q4 | $45.6M | Sell |
358,774
-264,564
| -42% | -$33.2M | 7.61% | 4 |
|
|
2017
Q3 | $73.2M | Sell |
623,338
-417,269
| -40% | -$35.6M | 12.75% | 1 |
|
|
2017
Q2 | $83M | Sell |
1,040,607
-51,909
| -5% | -$3.32M | 17.5% | 1 |
|
|
2017
Q1 | $56M | Buy |
1,092,516
+303,308
| +38% | +$14M | 14.74% | 1 |
|
|
2016
Q4 | $29.5M | Sell |
789,208
-159,078
| -17% | -$6.66M | 11.12% | 3 |
|
|
2016
Q3 | $64.3M | Buy |
948,286
+115,737
| +14% | +$8.17M | 19.43% | 1 |
|
|
2016
Q2 | $46.2M | Sell |
832,549
-33,830
| -4% | -$2.13M | 15.78% | 1 |
|
|
2016
Q1 | $54.4M | Buy |
866,379
+293,018
| +51% | +$19.5M | 19.74% | 1 |
|
|
2015
Q4 | $54M | Buy |
573,361
+39,701
| +7% | +$3.68M | 17.56% | 1 |
|
|
2015
Q3 | $42.9M | Buy |
533,660
+122,644
| +30% | +$13.6M | 13.32% | 1 |
|
|
2015
Q2 | $49.3M | Buy |
411,016
+55,621
| +16% | +$6.65M | 14.34% | 1 |
|
|
2015
Q1 | $37.1M | Buy |
355,395
+15,000
| +4% | +$1.52M | 16.75% | 1 |
|
|
2014
Q4 | $33M | Buy |
+340,395
| New | +$31.5M | 12.22% | 2 |
|
Other funds holding ALNY
RTW Investments's ALNY Position: Q1 2024 in Review
RTW Investments sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2024, closing a stake of 1,640,559 shares — an estimated $314M sold.
RTW Investments first reported a position in ALNY in Q4 2014 and held it in 37 quarters. The position peaked at $400M in Q4 2022. 498 funds tracked by Wall St. Rank hold ALNY as of Q1 2024.
- RTW Investments reported no remaining Alnylam Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
- RTW Investments sold 1,640,559 Alnylam Pharmaceuticals shares in Q1 2024, an estimated $314M.
- RTW Investments first reported a position in Alnylam Pharmaceuticals in Q4 2014 and held it in 37 quarters.
- RTW Investments's Alnylam Pharmaceuticals position peaked at $400M in Q4 2022.
- 498 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2024.
Based on RTW Investments's 13F filing for Q1 2024, filed 15 May 2024.